Varma et al., 2022 - Google Patents
LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a hamster model of …Varma et al., 2022
View HTML- Document ID
- 11590367999934951628
- Author
- Varma V
- Kadivella M
- Kumar A
- Kavela S
- Faisal S
- Publication year
- Publication venue
- Frontiers in Immunology
External Links
Snippet
Leptospirosis is a zoonotic disease of global importance. The current vaccine provides serovar-specific and short-term immunity and does not prevent bacterial shedding in infected animals. Subunit vaccines based on surface proteins have shown to induce …
- 230000028993 immune response 0 title abstract description 10
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cuadros et al. | Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses | |
| Didierlaurent et al. | Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells | |
| Varma et al. | LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a hamster model of leptospirosis | |
| Barazzone et al. | Revisiting the development of vaccines against pathogenic Leptospira: innovative approaches, present challenges, and future perspectives | |
| Kaba et al. | Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine | |
| Schijns et al. | Rational vaccine design in times of emerging diseases: The critical choices of immunological correlates of protection, vaccine antigen and immunomodulation | |
| Yu et al. | Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice | |
| Gupta et al. | Immunogenicity and protective efficacy of virus-like particles and recombinant fiber proteins in broiler-breeder vaccination against fowl adenovirus (FAdV)-8b | |
| Prochetto et al. | Trans-sialidase-based vaccine candidate protects against Trypanosoma cruzi infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype | |
| Gong et al. | Surface protein Adr2 of Rickettsia rickettsii induced protective immunity against Rocky Mountain spotted fever in C3H/HeN mice | |
| Mouhoub et al. | The diverse applications of recombinant BCG-based vaccines to target infectious diseases other than tuberculosis: an overview | |
| Gu et al. | A multiple antigen peptide vaccine containing CD4+ T cell epitopes enhances humoral immunity against Trichinella spiralis infection in mice | |
| Dinc et al. | Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant | |
| Grover et al. | High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines | |
| Whitlock et al. | Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge | |
| Gupta et al. | TcG2/TcG4 DNA vaccine induces Th1 immunity against acute Trypanosoma cruzi infection: adjuvant and antigenic effects of heterologous T. rangeli booster immunization | |
| de León et al. | Swine T-cells and specific antibodies evoked by peptide dendrimers displaying different FMDV T-cell epitopes | |
| Jawale et al. | Comparative evaluation of Salmonella Enteritidis ghost vaccines with a commercial vaccine for protection against internal egg contamination with Salmonella | |
| Fratzke et al. | Immunogenicity and reactogenicity in Q fever vaccine development | |
| Bergmann-Leitner et al. | Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria | |
| Dorneles et al. | Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans | |
| AU2014312135A1 (en) | Enhancing immunity to tuberculosis | |
| Zhu et al. | Evaluation and characteristics of immunological adjuvant activity of purified fraction of Albizia julibrissin saponins | |
| Techawiwattanaboon et al. | Designing adjuvant formulations to promote immunogenicity and protective efficacy of leptospira immunoglobulin-like protein A subunit vaccine | |
| Lu et al. | DNA vaccine ROP 29 from Toxoplasma gondii containing R848 enhances protective immunity in mice |